Cite
HARVARD Citation
Nash, P. et al. (n.d.). OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s). Annals of the rheumatic diseases. p. 135. [Online].